This mechanism leads to delayed gastric emptying, increased satiety, and a decreased desire for high-calorie, high-fat foods
Like other GLP-1 analogues, it acts on GLP-1 receptors to increase insulin secretion and decrease glucagon levels, leading to better blood sugar control and feelings of fullness
That will help scientists paint a more realistic portrait of the drugs strengths and weaknesses as treatments for different diseases
VK2735 was well tolerated, with mostly mild/moderate adverse events and low discontinuations
These developments raised several questions, including concerns about the direct and indirect impacts of these anti-obesity drugs on bone metabolism, particularly in PwO experiencing a massive amount of weight loss
According to the FDA, GLP-1s are approved for people with obesity (BMI of 30 or higher)